8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Mar 25, 2026·SEC
Journey Medical Corporation(DERM)Earnings, Financials & Key Ratios
DERM•NASDAQ
Price updated Jun 19, 2026
AboutJourney Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.Show more
- Revenue$62M+10.2%
- EBITDA-$4M+62.3%
- Net Income-$11M+22.1%
- EPS (Diluted)-0.47+34.7%
- Gross Margin59.29%-5.6%
- EBITDA Margin-6.19%+65.8%
- Operating Margin-13.21%+45.8%
- Net Margin-18.48%+29.3%
- ROE-44.03%+39.3%
DERM Key Insights
Journey Medical Corporation (DERM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 19.9% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DERM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DERM Price & Volume
Journey Medical Corporation (DERM) stock price & volume — 10-year historical chart
Loading chart...
DERM Growth Metrics
Journey Medical Corporation (DERM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years23.82%
5 Years6.79%
3 Years-5.66%
TTM15%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-15.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM6.33%
Return on Capital
10 Years-35.21%
5 Years-44.33%
3 Years-18.61%
Last Year-15.99%
DERM Recent Earnings
Journey Medical Corporation (DERM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.08-14.3%
$0.07
Rev
$16M+3.2%
$15M
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.04+33.3%
$0.06
Rev
$16M-14.7%
$19M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.09-12.5%
$0.08
Rev
$18M-6.5%
$19M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.16-128.6%
$0.07
Rev
$15M-20.6%
$19M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.08vs $0.07-14.3% | $16Mvs $15M+3.2% |
| Q2 2026 | Mar 25, 2026 | $0.04vs $0.06+33.3% | $16Mvs $19M-14.7% |
| Q4 2025 | Nov 12, 2025 | $0.09vs $0.08-12.5% | $18Mvs $19M-6.5% |
| Q3 2025 | Aug 12, 2025 | $0.16vs $0.07-128.6% | $15Mvs $19M-20.6% |
Based on last 12 quarters of dataView full earnings history →
DERM Peer Comparison
Journey Medical Corporation (DERM) competitors in Specialty pharma brand consolidators — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SKIN | 85.9M | 0.66 | -4.14 | -10.02% | -2.03% | -9.41% | 6.20 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 PODD | 10.23B | 145.76 | 41.89 | 30.73% | 10.44% | 21.38% | 0.69 | |
 VYNE | 27.17M | 0.64 | -1.02 | 13.77% | -47.26% | -69.57% | ||
 PCRX | 878.35M | 22.33 | 139.56 | 3.63% | 1.27% | 1.31% | 0.66 | |
 MCK | 90.23B | 750.63 | 19.56 | 12.36% | 1.18% | |||
 CAH | 52.19B | 221.77 | 34.38 | -1.87% | 0.62% |
Compare DERM vs Peers
Journey Medical Corporation (DERM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DERM Income Statement
Journey Medical Corporation (DERM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 4.54M | 42.34M | 34.92M | 44.53M | 63.13M | 73.67M | 79.18M | 56.13M | 61.86M | 64.68M |
Revenue Growth % | -79.89% | 832.37% | -17.52% | 27.52% | 41.78% | 16.69% | 7.48% | -29.11% | 10.2% | 15% |
Cost of Goods Sold | 0 | 1.18M | 10.53M | 14.59M | 32.08M | 30.77M | 26.66M | 20.88M | 25.18M | 25.61M |
COGS % of Revenue | - | 2.78% | 30.16% | 32.77% | 50.82% | 41.77% | 33.67% | 37.19% | 40.71% | - |
Gross Profit | 4.54M▲ 0% | 41.16M▲ 806.5% | 24.39M▼ 40.8% | 29.94M▲ 22.7% | 31.05M▲ 3.7% | 42.89M▲ 38.1% | 52.52M▲ 22.4% | 35.26M▼ 32.9% | 36.68M▲ 4.0% | 39.07M▲ 0% |
Gross Margin % | 100% | 97.22% | 69.84% | 67.23% | 49.18% | 58.23% | 66.33% | 62.81% | 59.29% | 60.41% |
Gross Profit Growth % | -79.89% | 806.47% | -40.75% | 22.75% | 3.72% | 38.14% | 22.44% | -32.87% | 4.03% | - |
Operating Expenses | 304.87M | 255.15M | 19.13M | 22.09M | 65.93M | 70.41M | 54.59M | 48.93M | 44.85M | 45.41M |
OpEx % of Revenue | 6713.65% | 602.62% | 54.78% | 49.6% | 104.43% | 95.58% | 68.95% | 87.17% | 72.5% | - |
Selling, General & Admin | 71.9M | 172.58M | 19.13M | 0 | 39.83M | 59.47M | 43.91M | 40.2M | 44.37M | 31.85M |
SG&A % of Revenue | 1583.42% | 407.62% | 54.78% | - | 63.09% | 80.72% | 55.46% | 71.62% | 71.73% | - |
Research & Development | 104.41M | 80.55M | 0 | 0 | 16.56M | 10.94M | 7.54M | 9.86M | 480K | 441K |
R&D % of Revenue | 2299.25% | 190.24% | - | - | 26.23% | 14.85% | 9.52% | 17.56% | 0.78% | - |
Other Operating Expenses | 128.56M | 2.02M | 0 | 22.09M | 9.54M | 0 | 3.14M | -1.13M | 0 | 1000K |
Operating Income | -300.33M▲ 0% | -213.98M▲ 28.8% | 5.26M▲ 102.5% | 7.85M▲ 49.3% | -34.88M▼ 544.3% | -27.52M▲ 21.1% | -2.07M▲ 92.5% | -13.68M▼ 559.8% | -8.17M▲ 40.3% | -6.34M▲ 0% |
Operating Margin % | -6613.65% | -505.4% | 15.06% | 17.63% | -55.25% | -37.35% | -2.62% | -24.36% | -13.21% | -9.8% |
Operating Income Growth % | -231.4% | 28.75% | 102.46% | 49.29% | -544.29% | 21.11% | 92.47% | -559.77% | 40.25% | - |
EBITDA | -299.99M | -213.43M | 6.46M | 9.28M | -32.32M | -23.15M | 1.78M | -10.16M | -3.83M | -1.95M |
EBITDA Margin % | -6606.19% | -504.09% | 18.51% | 20.83% | -51.19% | -31.43% | 2.25% | -18.1% | -6.19% | -3.02% |
EBITDA Growth % | -231.47% | 28.85% | 103.03% | 43.5% | -448.44% | 28.37% | 107.7% | -670.26% | 62.35% | 37.92% |
D&A (Non-Cash Add-back) | 339K | 555K | 1.21M | 1.43M | 2.56M | 4.37M | 3.85M | 3.52M | 4.35M | 4.39M |
EBIT | -295.12M | -206.09M | 5.26M | 7.85M | -35.33M | -27.55M | -1.93M | -11.91M | -8.17M | -6.19M |
Net Interest Income | 0 | 0 | -255K | -698K | -7.03M | -1.96M | -1.38M | -1.94M | -3.11M | -3.1M |
Interest Income | 0 | 0 | 0 | 0 | 2K | 60K | 322K | 757K | 589K | 597K |
Interest Expense | 8.14M | 15.64M | 255K | 698K | 7.03M | 2.02M | 1.7M | 2.7M | 3.7M | 3.7M |
Other Income/Expense | -2.94M | -7.75M | -255K | -698K | -7.48M | -2.05M | -1.56M | -934K | -3.2M | -3.19M |
Pretax Income | -303.26M▲ 0% | -221.73M▲ 26.9% | 5M▲ 102.3% | 7.15M▲ 42.9% | -42.36M▼ 692.2% | -29.57M▲ 30.2% | -3.63M▲ 87.7% | -14.61M▼ 302.3% | -11.37M▲ 22.2% | -9.53M▲ 0% |
Pretax Margin % | -6678.29% | -523.71% | 14.33% | 16.06% | -67.1% | -40.13% | -4.59% | -26.03% | -18.38% | -14.73% |
Income Tax | 0 | -194K | 1.38M | 1.87M | 1.63M | 63K | 221K | 61K | 60K | 60K |
Effective Tax Rate % | 0% | 0.09% | 27.56% | 26.14% | -3.86% | -0.21% | -6.08% | -0.42% | -0.53% | -0.63% |
Net Income | -303.26M▲ 0% | -221.54M▲ 26.9% | 3.63M▲ 101.6% | 5.28M▲ 45.7% | -43.99M▼ 932.7% | -29.63M▲ 32.7% | -3.85M▲ 87.0% | -14.67M▼ 280.8% | -11.43M▲ 22.1% | -9.59M▲ 0% |
Net Margin % | -6678.29% | -523.25% | 10.38% | 11.86% | -69.68% | -40.22% | -4.87% | -26.14% | -18.48% | -14.82% |
Net Income Growth % | -240.42% | 26.95% | 101.64% | 45.74% | -932.75% | 32.65% | 87% | -280.79% | 22.09% | -15.48% |
Net Income (Continuing) | -303.26M | -221.54M | 3.63M | 5.28M | -43.99M | -29.63M | -3.85M | -14.67M | -11.43M | -9.59M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -7.48▲ 0% | -5.27▲ 29.5% | 0.22▲ 104.2% | 0.32▲ 45.5% | -2.54▼ 893.8% | -1.69▲ 33.5% | -0.21▲ 87.6% | -0.72▼ 242.9% | -0.47▲ 34.7% | -0.35▲ 0% |
EPS Growth % | -177.04% | 29.55% | 104.17% | 45.45% | -893.75% | 33.46% | 87.57% | -242.86% | 34.72% | 6.33% |
EPS (Basic) | -7.48 | -5.27 | 0.22 | 0.32 | -2.54 | -1.69 | -0.21 | -0.72 | -0.47 | - |
Diluted Shares Outstanding | 40.56M | 42M | 16.66M | 16.66M | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M | 27.31M |
Basic Shares Outstanding | 40.56M | 42M | 16.66M | 16.66M | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M | 27.31M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
DERM Balance Sheet
Journey Medical Corporation (DERM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 556.61M | 335.41M | 25.27M | 35.24M | 84.49M | 77.68M | 56.45M | 48.18M | 66.87M | 64.97M |
Cash & Short-Term Investments | 550.99M | 313.04M | 4.8M | 8.25M | 49.08M | 32M | 27.44M | 20.3M | 24.09M | 27.22M |
Cash Only | 295.92M | 104.98M | 4.8M | 8.25M | 49.08M | 32M | 27.44M | 20.3M | 24.09M | 27.22M |
Short-Term Investments | 255.07M | 208.06M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 52K | 5.72M | 18.95M | 23.93M | 23.11M | 28.21M | 15.22M | 10.23M | 29.78M | 24.99M |
Days Sales Outstanding | 4.18 | 49.35 | 198.12 | 196.13 | 133.62 | 139.76 | 70.17 | 66.53 | 175.74 | 124.72 |
Inventory | 0 | 8.37M | 857K | 1.4M | 9.86M | 14.16M | 10.21M | 14.43M | 9.62M | 9.29M |
Days Inventory Outstanding | - | 2.6K | 29.7 | 35.11 | 112.19 | 167.93 | 139.73 | 252.28 | 139.49 | 155.32 |
Other Current Assets | 5.57M | 8.28M | 0 | 0 | 2.44M | 3.31M | 3.59M | 3.21M | 3.38M | 3.46M |
Total Non-Current Assets | 4.18M | 8.91M | 8.59M | 16.66M | 12.79M | 27.48M | 20.39M | 32.06M | 27.72M | 26.57M |
Property, Plant & Equipment | 1.43M | 1.18M | 89K | 175K | 89K | 189K | 101K | 199K | 111K | 88K |
Fixed Asset Turnover | 3.17x | 35.88x | 392.37x | 254.46x | 709.37x | 389.78x | 783.97x | 282.08x | 557.28x | 529.08x |
Goodwill | 771K | 771K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 1.13M | 952K | 7.38M | 15.03M | 12.55M | 27.2M | 20.29M | 31.86M | 27.61M | 26.48M |
Long-Term Investments | 0 | 2.96M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 656K | 3.05M | 6K | 6K | 150K | 95K | 6K | 0 | 0 | 0 |
Total Assets | 560.79M▲ 0% | 344.32M▼ 38.6% | 33.86M▼ 90.2% | 51.91M▲ 53.3% | 97.28M▲ 87.4% | 105.16M▲ 8.1% | 76.85M▼ 26.9% | 80.24M▲ 4.4% | 94.59M▲ 17.9% | 91.53M▲ 0% |
Asset Turnover | 0.01x | 0.12x | 1.03x | 0.86x | 0.65x | 0.70x | 1.03x | 0.70x | 0.65x | 0.73x |
Asset Growth % | 79.4% | -38.6% | -90.17% | 53.3% | 87.42% | 8.1% | -26.92% | 4.41% | 17.88% | 83.13% |
Total Current Liabilities | 105.36M | 38.56M | 20.9M | 28.06M | 51.61M | 66.83M | 41.87M | 35.17M | 37.44M | 37.83M |
Accounts Payable | 15.09M | 15.95M | 2.11M | 1.96M | 22.81M | 36.98M | 16.08M | 16.05M | 9.31M | 8.2M |
Days Payables Outstanding | - | 4.95K | 73.06 | 48.92 | 259.52 | 438.63 | 220.16 | 280.58 | 134.89 | 149.02 |
Short-Term Debt | 4.63M | 0 | 0 | 4.52M | 812K | 2.95M | 3M | 625K | 101K | 2.59M |
Deferred Revenue (Current) | 4.99M | 0 | 0 | 0 | 0 | 0 | 53K | 0 | 0 | 0 |
Other Current Liabilities | 80.65M | 22.61M | 7.09M | 2.58M | 24.59M | 14.1M | 4.08M | 14.45M | 27.96M | 27.03M |
Current Ratio | 5.28x | 8.70x | 1.21x | 1.26x | 1.64x | 1.16x | 1.35x | 1.37x | 1.79x | 1.72x |
Quick Ratio | 5.28x | 8.48x | 1.17x | 1.21x | 1.45x | 0.95x | 1.10x | 0.96x | 1.53x | 1.47x |
Cash Conversion Cycle | - | -2.3K | 154.77 | 182.32 | -13.71 | -130.94 | -10.27 | 38.22 | 180.35 | 131.01 |
Total Non-Current Liabilities | 305.79M | 314.8M | 10.21M | 13.55M | 3.63M | 21.35M | 14.63M | 25M | 25.3M | 22.87M |
Long-Term Debt | 279.39M | 313.79M | 5.22M | 5.22M | 0 | 19.83M | 14.62M | 24.88M | 18K | 22.87M |
Capital Lease Obligations | 0 | 0 | 0 | 97K | 0 | 108K | 9K | 118K | 0 | 113K |
Deferred Tax Liabilities | 194K | 0 | 0 | 99K | 8K | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 918K | 1.01M | 4.99M | 8.24M | 3.63M | 1.41M | 0 | 0 | 25.28M | 0 |
Total Liabilities | 411.14M | 353.36M | 31.11M | 41.61M | 55.24M | 88.18M | 56.5M | 60.17M | 62.74M | 60.7M |
Total Debt | 279.39M | 313.79M | 5.3M | 9.92M | 910K | 22.96M | 17.73M | 25.7M | 119K | 25.47M |
Net Debt | -16.53M | 208.81M | 502K | 1.68M | -48.17M | -9.04M | -9.71M | 5.4M | -23.97M | -1.75M |
Debt / Equity | 1.87x | - | 1.93x | 0.96x | 0.02x | 1.35x | 0.87x | 1.28x | 0.00x | 0.83x |
Debt / EBITDA | - | - | 0.82x | 1.07x | - | - | 9.95x | - | - | -13.04x |
Net Debt / EBITDA | - | - | 0.08x | 0.18x | - | - | -5.45x | - | - | 0.90x |
Interest Coverage | -36.26x | -13.18x | 20.62x | 11.25x | -5.02x | -13.64x | -1.14x | -4.41x | -2.21x | -1.67x |
Total Equity | 149.65M▲ 0% | -9.04M▼ 106.0% | 2.75M▲ 130.4% | 10.29M▲ 274.0% | 42.04M▲ 308.5% | 16.98M▼ 59.6% | 20.35M▲ 19.8% | 20.07M▼ 1.4% | 31.85M▲ 58.7% | 30.83M▲ 0% |
Equity Growth % | -39.5% | -106.04% | 130.45% | 273.98% | 308.5% | -59.61% | 19.83% | -1.38% | 58.71% | 309.26% |
Book Value per Share | 3.69 | -0.22 | 0.17 | 0.62 | 2.43 | 0.97 | 1.12 | 0.98 | 1.30 | 1.13 |
Total Shareholders' Equity | 149.65M | -9.04M | 2.75M | 10.29M | 42.04M | 16.98M | 20.35M | 20.07M | 31.85M | 30.83M |
Common Stock | 42K | 42K | 1K | 1K | 2K | 2K | 2K | 2K | 2K | 2K |
Retained Earnings | -553.39M | -745.04M | -163K | 5.12M | -38.87M | -68.5M | -72.36M | -87.03M | -98.46M | -100.69M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -511K | -1.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DERM Cash Flow Statement
Journey Medical Corporation (DERM) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -103.96M | -213.1M | 9.02M | 5.13M | -2.18M | -13.53M | 5.24M | -9.13M | -12.44M | -6.78M |
Operating CF Margin % | -2289.43% | -503.31% | 25.82% | 11.52% | -3.45% | -18.37% | 6.62% | -16.26% | -20.11% | - |
Operating CF Growth % | -40.28% | -104.97% | 104.23% | -43.09% | -142.5% | -520.54% | 138.72% | -274.18% | -36.31% | -207.24% |
Net Income | -303.26M | -221.54M | 3.63M | 5.28M | -43.99M | -29.63M | -3.85M | -14.67M | -11.43M | -9.59M |
Depreciation & Amortization | 339K | 555K | 1.26M | 1.52M | 2.56M | 4.37M | 3.85M | 3.42M | 4.72M | 4.41M |
Stock-Based Compensation | 20.7M | 29.84M | 240K | 153K | 2.47M | 4.42M | 2.61M | 6.1M | 6.29M | 1.34M |
Deferred Taxes | 0 | -194K | 69K | -335K | 1.57M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -24M | 132.64M | 355K | 747K | 20.51M | 1.12M | 4.29M | -211K | -123K | 4.63M |
Working Capital Changes | 202.26M | -154.4M | 3.46M | -2.23M | 14.71M | 6.19M | -1.66M | -3.77M | -11.9M | -7.56M |
Change in Receivables | 21.35M | -5.67M | -10.49M | -5.02M | 768K | -5.38M | 12.55M | 4.47M | -19.34M | -6.59M |
Change in Inventory | -271.89M | -8.37M | -179K | -547K | -8.46M | 1.74M | 3.95M | -4.22M | 4.81M | 3.2M |
Change in Payables | 1.54M | 823K | 1.15M | -152K | 21.71M | 14.34M | -18.42M | -2.1M | -7.27M | -6.57M |
Cash from Investing | -104.43M | -13.23M | -2.4M | -1.2M | -10M | -20M | -5M | -15M | 0 | 0 |
Capital Expenditures | -278K | -616K | -2.4M | -1.2M | -10M | -20M | -5M | -15M | 0 | 0 |
CapEx % of Revenue | 6.12% | 1.45% | 6.87% | 2.69% | 15.84% | 27.15% | 6.31% | 26.72% | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -80.3M | -56M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 462.52M | 35.38M | -3.55M | -487K | 53.02M | 16.46M | -4.8M | 16.99M | 16.23M | 12.92M |
Debt Issued (Net) | 0 | 0 | -3.55M | -500K | 5.05M | 16.9M | -8.95M | 8.7M | -625K | 0 |
Equity Issued (Net) | 0 | 0 | 0 | 13K | 30.99M | -229K | 4.49M | 8.29M | 16.93M | 12.92M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 184.28M | 2.15M | 0 | 0 | 0 | -371K | 0 | 0 | 0 | 0 |
Other Financing | 462.52M | 35.38M | 0 | 0 | 16.97M | -214K | -350K | 0 | -75K | 0 |
Net Change in Cash | 254.13M▲ 0% | -190.94M▼ 175.1% | 3.07M▲ 101.6% | 3.44M▲ 12.3% | 40.84M▲ 1085.3% | -17.08M▼ 141.8% | -4.56M▲ 73.3% | -7.13M▼ 56.3% | 3.79M▲ 153.1% | 6.15M▲ 0% |
Free Cash Flow | -104.24M▲ 0% | -213.71M▼ 105.0% | 6.62M▲ 103.1% | 3.93M▼ 40.6% | -12.18M▼ 409.8% | -33.53M▼ 175.3% | 240K▲ 100.7% | -9.13M▼ 3902.9% | -12.44M▼ 36.3% | -6.78M▲ 0% |
FCF Margin % | -2295.55% | -504.77% | 18.95% | 8.83% | -19.29% | -45.52% | 0.3% | -16.26% | -20.11% | -10.47% |
FCF Growth % | -39.24% | -105.02% | 103.1% | -40.59% | -409.79% | -175.3% | 100.72% | -3902.92% | -36.31% | 2.38% |
FCF per Share | -2.57 | -5.09 | 0.40 | 0.24 | -0.70 | -1.91 | 0.01 | -0.45 | -0.51 | -0.25 |
FCF Conversion (FCF/Net Income) | 0.34x | 0.96x | 2.49x | 0.97x | 0.05x | 0.46x | -1.36x | 0.62x | 1.09x | 0.71x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 993K | 1.13M | 2.01M | 0 | 1.59M |
Taxes Paid | 0 | 0 | 192K | 110K | 158K | 168K | 181K | 125K | 0 | 49K |
DERM Key Ratios
Journey Medical Corporation (DERM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -152.77% | -315.11% | 131.72% | 81% | -168.12% | -100.39% | -20.64% | -72.6% | -44.03% | -35.57% |
Return on Invested Capital (ROIC) | -133.01% | -96.42% | 3.89% | 77.35% | -895.61% | -2272.88% | -16.73% | -56.81% | -36.76% | -21.75% |
Gross Margin | 100% | 97.22% | 69.84% | 67.23% | 49.18% | 58.23% | 66.33% | 62.81% | 59.29% | 60.41% |
Net Margin | -6678.29% | -523.25% | 10.38% | 11.86% | -69.68% | -40.22% | -4.87% | -26.14% | -18.48% | -14.82% |
Debt / Equity | 1.87x | - | 1.93x | 0.96x | 0.02x | 1.35x | 0.87x | 1.28x | 0.00x | 0.83x |
Interest Coverage | -36.26x | -13.18x | 20.62x | 11.25x | -5.02x | -13.64x | -1.14x | -4.41x | -2.21x | -1.67x |
FCF Conversion | 0.34x | 0.96x | 2.49x | 0.97x | 0.05x | 0.46x | -1.36x | 0.62x | 1.09x | 0.71x |
Revenue Growth | -79.89% | 832.37% | -17.52% | 27.52% | 41.78% | 16.69% | 7.48% | -29.11% | 10.2% | 15% |
Related:DERM Dividend History·DERM Revenue History·DERM Price History·DERM P/E History·DERM Financial Ratios·DERM Institutional Holders
DERM SEC Filings & Documents
Journey Medical Corporation (DERM) SEC filings — annual & quarterly reports (10-K, 10-Q)
DERM Frequently Asked Questions
Journey Medical Corporation (DERM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Journey Medical Corporation (DERM) reported $64.7M in revenue for fiscal year 2025. This represents a 786% increase from $7.3M in 2014.
Journey Medical Corporation (DERM) grew revenue by 10.2% over the past year. This is steady growth.
Journey Medical Corporation (DERM) reported a net loss of $9.6M for fiscal year 2025.
Dividend & Returns
Journey Medical Corporation (DERM) has a return on equity (ROE) of -44.0%. Negative ROE indicates the company is unprofitable.
Journey Medical Corporation (DERM) had negative free cash flow of $6.8M in fiscal year 2025, likely due to heavy capital investments.